Overview Request Sample Pages Request Customization Download PDF
You are viewing: Brazil Preimplantation Genetic Testing Market analysis

The Brazil Preimplantation Genetic Testing Market was valued at $7.7 Million in 2025 and projected to reach to $12.6 Million by 2030, representing a compound annual growth rate of 10.2%. Brazil's preimplantation genetic testing market is positioned for steady growth as reproductive medicine advances and healthcare infrastructure improves across the country.

Brazil Preimplantation Genetic Testing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Brazil Preimplantation Genetic Testing Market Trends and Insights

  • This growth trajectory reflects Brazil's increasing adoption of advanced reproductive technologies and rising awareness among fertility clinics and patients regarding genetic screening benefits.
  • Brazil's market expansion is driven by improving healthcare infrastructure, growing middle-class demand for assisted reproductive services, and enhanced regulatory frameworks supporting genetic testing in fertility treatment. The Brazilian PGT market demonstrates resilience and opportunity within Latin America's broader fertility sector.
  • Brazil's 10.2% compound annual growth rate (CAGR) through 2030 underscores strong demand for genetic diagnostic capabilities in reproductive medicine.
  • Brazil's market development is supported by increasing investment in fertility centers, rising disposable incomes, and greater acceptance of genetic testing as a standard component of in vitro fertilization (IVF) protocols.
  • Brazil's competitive landscape continues to attract both domestic and international diagnostic providers seeking to establish or expand their presence in this growing market..

Key Market Statistics

  • CAGR (2025-2030) 10.2% CAGR
  • Market Size, 2025 ~USD 7.7 Million
  • Forecast, 2030 ~USD 12.6 Million
  • Country Brazil

Brazil Preimplantation Genetic Testing Market Overview

Market Valuation Growth :

Brazil's PGT market is valued at $7.7 million in 2025, with projections reaching $12.6 million by 2030, representing a robust 10.2% CAGR over the forecast period.

Rising Fertility Clinic Adoption :

Brazilian fertility clinics are increasingly integrating advanced reproductive technologies, with PGT becoming a standard offering in major metropolitan centers like São Paulo and Rio de Janeiro.

Patient Awareness Expansion :

Growing patient education and awareness campaigns about genetic screening benefits are driving demand for PGT services across Brazil's middle and upper-income demographics.

Regulatory Environment Development :

Brazil's healthcare regulatory framework is evolving to support advanced reproductive technologies, creating favorable conditions for market expansion and clinical adoption.

Brazil Preimplantation Genetic Testing Market Dynamics

  • The increasing prevalence of advanced maternal age, coupled with rising disposable incomes in urban centers, is driving demand for genetic screening services.
  • Fertility clinics in Brazil are investing in cutting-edge diagnostic technologies to meet patient expectations for comprehensive genetic analysis. The market outlook remains positive through 2030, supported by growing medical professional endorsement of PGT and expanding insurance coverage for fertility treatments.
  • As Brazil's healthcare system continues modernizing and patient access to reproductive services improves, the PGT market is expected to benefit from increased clinic adoption and higher procedure volumes across the country..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • Brazil's PGT market is valued at $7.7 million in 2025 and is forecast to grow to $12.6 million by 2030, representing a 10.2% CAGR.
      • Brazil's market growth is driven by increased adoption of assisted reproductive technologies and rising patient awareness of genetic screening benefits.
      • Brazil's expanding middle class and improving healthcare infrastructure are key factors supporting market expansion through 2030.
      • Brazil's fertility sector is attracting significant investment from both domestic and international diagnostic providers seeking market opportunities.

      Preimplantation Genetic Testing Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment SINGLE GENE DISORDERS (Application)
      Forecast Period 2025–2030
      Growth Rate CAGR of 10.5% from 2025 to 2030
      Largest Segment PREIMPLANTATION GENETIC SCREENING (Procedure Type)
      Market Size Base Year (Billions) ~USD 0.69 (2025)
      Revenue Forecast (Billions) ~USD 1.14 (2030)
      Segments Covered Product & Service, Procedure Type, Technology, Application, Type, Type Of Cycle, End User

      Brazil Preimplantation Genetic Testing Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Product & Service

      • Instruments
      • Reagents & Consumables
      • Software & Services

      By Procedure Type

      • Preimplantation Genetic Diagnosis
      • Preimplantation Genetic Screening

      By Technology

      • Comparative Genomic Hybridization
      • Fluorescence In Situ Hybridization
      • Next-Generation Sequencing
      • Polymerase Chain Reaction
      • Single-Nucleotide Polymorphism

      By Application

      • Aneuploidy
      • Gender Identification
      • Hla Typing
      • Single Gene Disorders
      • Structural Chromosomal Abnormalities
      • X-Linked Disorders

      By Type

      • Deletions
      • Duplications
      • Inversions
      • Translocations

      By Type Of Cycle

      • Fresh Donor
      • Fresh Non-Donor
      • Frozen Donor
      • Frozen Non-Donor

      By End User

      • Diagnostic Laboratories
      • Fertility Clinics
      • Hospitals
      • Other End Users

      BRAZIL: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030

      Segment20232024202520262027202820292030CAGR (%)
      DIAGNOSTIC LABORATORIES2.042.192.382.622.883.193.543.9410.6
      FERTILITY CLINICS5.816.216.717.338.038.849.7610.810
      HOSPITALS1.461.551.661.81.952.132.322.558.9
      OTHER END USERS0.540.570.60.650.70.750.820.898.1
      TOTAL9.8410.5311.3612.3913.5614.9116.4418.189.9

      Target Audience

      • Fertility Clinic Operators : Clinic owners and medical directors need Brazil-specific market data to evaluate PGT service expansion, benchmark against competitors, and justify technology investments to stakeholders.
      • Diagnostic Equipment Manufacturers : Medical device and genetic testing companies require detailed Brazil market insights to develop localized sales strategies, identify clinic partnerships, and forecast revenue potential.
      • Healthcare Investors & PE Firms : Investment professionals evaluating reproductive health opportunities in Brazil need comprehensive market analysis, growth projections, and competitive dynamics to assess investment viability.
      • Healthcare Consultants : Management consultants advising fertility and reproductive health clients require Brazil-specific market data, trend analysis, and forecasts to develop informed strategic recommendations.
      • Insurance & Reimbursement Specialists : Insurance companies and healthcare administrators need Brazil market intelligence on PGT adoption rates, patient demand, and coverage trends to inform policy and pricing decisions.

      Key Companies in the Brazil Preimplantation Genetic Testing Market

      CompanyHQOwnershipStrongest segments
      CIMARON LABELPressure-sensitive paper labels,Film and durable labels,Specialty/custom applications,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLaboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      REVVITYUnited StatesPublic CompanyReagents, Assays, and Consumables,Instruments and Detection/Imaging Platforms,Software, Subscriptions, and Informatics,
      COOPERCOMPANIESUnited StatesPublic CompanySpherical contact lenses,Toric and multifocal contact lenses,Fertility consumables, equipment, and services,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      TAKARA BIO INC.JapanPrivate CompanyResearch reagents for genetic and cellular research,Instruments (PCR instruments and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
      VITROLIFESwedenPublic CompanyIVF media and oil,Labware (dishes, pipettes, tubes, VitroTemp, eWitness-related consumables),Cryopreservation solutions,

      CIMARON LABEL

      Insufficient information provided to generate description.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science, providing laboratory equipment, reagents, and analytical instruments.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company provides life sciences, diagnostics, and applied chemical markets with instruments and software.

      REVVITY

      Revvity is a United States-based public company founded in 1937 with 11,000 employees. The company provides analytical technologies and solutions for research, diagnostics, and applied markets.

      COOPERCOMPANIES

      CooperCompanies is a United States-based public company founded in 1958 with 15,000 employees. The company operates in the medical device sector, primarily focused on contact lenses and eye care products.

      ABBOTT

      Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company is a diversified healthcare manufacturer producing pharmaceuticals, diagnostics, nutritional products, and medical devices.

      TAKARA BIO INC.

      Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company specializes in biotechnology research and development.

      VITROLIFE

      Vitrolife is a Sweden-based public company founded in 1989 with 1,103 employees. The company develops and manufactures products for assisted reproduction and embryo culture.

      Reasons to Buy this Report

      • Market Size & Growth Validation : Obtain precise market valuation data for Brazil's PGT sector with verified CAGR figures (10.2%) and forecasts through 2030, enabling accurate business planning and investment decisions.
      • Competitive Landscape Intelligence : Understand Brazil-specific market dynamics, fertility clinic adoption patterns, and regional competitive positioning to identify market entry opportunities and strategic partnerships.
      • Patient Demand Insights : Access detailed analysis of Brazilian patient demographics, awareness levels, and demand drivers to tailor marketing strategies and service offerings for maximum market penetration.
      • Regulatory & Reimbursement Analysis : Gain comprehensive understanding of Brazil's healthcare regulatory environment, insurance coverage trends, and reimbursement policies affecting PGT market growth and profitability.
      • Strategic Growth Opportunities : Identify high-potential geographic markets within Brazil, emerging clinic partnerships, and expansion strategies to capitalize on the projected $4.9 million market growth by 2030.

      Frequently asked questions

      What is the current size of Brazil's preimplantation genetic testing market?

      Brazil's PGT market is valued at $7.7 million in 2025 and is expected to reach $12.6 million by 2030.

      What is the projected growth rate for Brazil's PGT market?

      Brazil's PGT market is projected to grow at a compound annual growth rate (CAGR) of 10.2% from 2025 to 2030.

      What factors are driving growth in Brazil's PGT market?

      Brazil's market growth is driven by increased adoption of assisted reproductive technologies, rising patient awareness, improving healthcare infrastructure, and growing middle-class demand for fertility services.

      How does Brazil's PGT market compare to other Latin American countries?

      Brazil represents a significant portion of Latin America's PGT market due to its large population, developed healthcare system, and high demand for assisted reproductive services.

      What regulatory environment supports Brazil's PGT market development?

      Brazil has established regulatory frameworks that support genetic testing in fertility treatment, enabling market expansion and attracting both domestic and international diagnostic providers.

      RESEARCH METHODOLOGY

      This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global preimplantation genetic testing market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives, and industry consultants, to obtain and verify important qualitative and quantitative data and evaluate the market’s growth prospects. The global market size estimated through secondary research was cross-checked with inputs from primary research to determine the final market size.

      Secondary Research

      Secondary research was mainly used to gather information for the detailed technical, market, and commercial analysis of the preimplantation genetic testing market. The secondary sources for this study include the World Health Organization (WHO), World Bank, Human Fertilization and Embryology Authority (HFEA), International Federation of Fertility Societies (IFFS), American Society for Reproductive Medicine (ASRM), Australia and New Zealand Assisted Reproduction Database (ANZARD), Centers for Disease Control and Prevention (CDC), Society for Assisted Reproductive Technology (SART), National Health Service (NHS), Indian Fertility Society (IFS), British Fertility Society (BFS), European Society of Human Reproduction and Embryology (ESHRE), Association for Fertility and Reproductive Health (AFRH), German Society of Reproductive Medicine (DGRM), Canadian Fertility & Andrology Society (CFAS), Indian Society for the Study of Reproduction and Fertility (ISSRF), Spanish Fertility Society (Sociedad Española de Fertilidad-SEF), Japan Society for Reproductive Medicine, National Registry of Assisted Reproductive Technology and Surrogacy Registry, Journal of Human Reproductive Sciences, American Congress of Obstetricians and Gynecologists (ACOG), European Society of Human Genetics (ESHG); ACS Journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.

      Secondary data was collected and analyzed to determine the overall size of the global preimplantation genetic testing market, which was then validated through primary research. These sources also provided key information about major players, market classification, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

      Preimplantation Genetic Testing Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the preimplantation genetic testing market. These methods were also used extensively to estimate the size of various market segments.

      Preimplantation Genetic Testing Market

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.

      Market Definition

      Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman's uterus. This is done to test a range of genetic problems that can cause implantation failure, miscarriage, and birth defects in a resulting child.

      Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:

      • Preimplantation genetic screening for abnormal chromosome number (PGT-A)
      • Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
      • Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.

      The study offers an in-depth analysis of the preimplantation genetic testing market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key preimplantation genetic testing product and service providers.

      Stakeholders

      • Contract research organizations (CROs)
      • Contract development and manufacturing organizations (CDMOs)
      • In vitro fertilization (IVF) centers and fertility clinics
      • Life science companies
      • Fertility clinics
      • Academic & research institutes
      • Private research institutes
      • Venture capitalists & investors
      • Market research & consulting firms
      • Government associations
      • Medical institutions & universities
      • Hospitals & clinics

      Report Objectives

      • To define, describe, and forecast the preimplantation genetic testing market based on procedure type, technology, product & service, application, type of cycle, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the preimplantation genetic testing market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the preimplantation genetic testing market
      • To benchmark players within the preimplantation genetic testing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

      Get the Full Preimplantation Genetic Testing Market Report

      Full forecast, segment splits, and company analysis for all Preimplantation Genetic Testing Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status